open access

Vol 8, No 7 (2007): Practical Diabetology
Original articles (submitted)
Published online: 2007-08-01
Get Citation

Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy

T.R. Pieber, H-C. Trechel, B. Hopmpsecht, A. Philotheou, L. Mordhorst, M-A. Gall, L.I. Robertson
Diabetologia Praktyczna 2007;8(7):270-279.

open access

Vol 8, No 7 (2007): Practical Diabetology
Original articles (submitted)
Published online: 2007-08-01

Abstract

BACKGROUND. To compare glycaemic control and risk of hypoglycaemia of twice-daily insulin detemir with once-daily insulin glargine in subjects with type 1 diabetes.
MATERIAL AND METHODS. In this 26-week, multicentre, open-label, parallel-group trial, 320 subjects with type 1 diabetes received either insulin detemir twice daily or insulin glargine once daily, each in combination with premeal insulin aspart.
RESULTS. After 26 weeks, HbA1c had decreased from 8.8 to 8.2% in the insulin detemir group and from 8.7% to 8.2% in the insulin glargine group. Homemeasured fasting plasma glucose (PG) was lower with insulin glargine than with insulin detemir (7.0 mmol/l vs. 7.7 mmol/l; p < 0.001). The overall shape of the home-measured nine-point PG profiles was comparable between treatments (p = 0.125). Overall, there was no significant difference in within-subject variation in PG (p = 0.437). Withinsubject variation in predinner PG was lower with insulin detemir than with insulin glargine (p < 0.05). The overall risk of hypoglycaemia was similar with no differences in confirmed hypoglycaemia. However, the risk of severe and nocturnal hypoglycaemia was 72% and 32%, respectively, lower with insulin detemir than with insulin glargine (p < 0.05). Body weight gain was not significantly different comparing insulin detemir and insulin glargine (0.52 kg vs. 0.96 kg, p = 0.193).
CONCLUSIONS. Treatment with twice-daily insulin detemir or once-daily insulin glargine, each in combination with insulin aspart, resulted in similar glycaemic control. The overall risk of hypoglycaemia was comparable, whereas the risks of both severe and nocturnal hypoglycaemia were significantly lower with insulin detemir.

Abstract

BACKGROUND. To compare glycaemic control and risk of hypoglycaemia of twice-daily insulin detemir with once-daily insulin glargine in subjects with type 1 diabetes.
MATERIAL AND METHODS. In this 26-week, multicentre, open-label, parallel-group trial, 320 subjects with type 1 diabetes received either insulin detemir twice daily or insulin glargine once daily, each in combination with premeal insulin aspart.
RESULTS. After 26 weeks, HbA1c had decreased from 8.8 to 8.2% in the insulin detemir group and from 8.7% to 8.2% in the insulin glargine group. Homemeasured fasting plasma glucose (PG) was lower with insulin glargine than with insulin detemir (7.0 mmol/l vs. 7.7 mmol/l; p < 0.001). The overall shape of the home-measured nine-point PG profiles was comparable between treatments (p = 0.125). Overall, there was no significant difference in within-subject variation in PG (p = 0.437). Withinsubject variation in predinner PG was lower with insulin detemir than with insulin glargine (p < 0.05). The overall risk of hypoglycaemia was similar with no differences in confirmed hypoglycaemia. However, the risk of severe and nocturnal hypoglycaemia was 72% and 32%, respectively, lower with insulin detemir than with insulin glargine (p < 0.05). Body weight gain was not significantly different comparing insulin detemir and insulin glargine (0.52 kg vs. 0.96 kg, p = 0.193).
CONCLUSIONS. Treatment with twice-daily insulin detemir or once-daily insulin glargine, each in combination with insulin aspart, resulted in similar glycaemic control. The overall risk of hypoglycaemia was comparable, whereas the risks of both severe and nocturnal hypoglycaemia were significantly lower with insulin detemir.
Get Citation

Keywords

HbA1c; hypoglycaemia; insulin detemir; insulin glargine; type 1 diabetes

About this article
Title

Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy

Journal

Clinical Diabetology

Issue

Vol 8, No 7 (2007): Practical Diabetology

Pages

270-279

Published online

2007-08-01

Bibliographic record

Diabetologia Praktyczna 2007;8(7):270-279.

Keywords

HbA1c
hypoglycaemia
insulin detemir
insulin glargine
type 1 diabetes

Authors

T.R. Pieber
H-C. Trechel
B. Hopmpsecht
A. Philotheou
L. Mordhorst
M-A. Gall
L.I. Robertson

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl